{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:20:20Z","timestamp":1792160420757,"version":"4.4.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sickle cell disease is a disorder characterized by chronic hemolytic anemia and multiorgan disease complications. Although vaso-occlusive episodes, acute chest syndrome, and neurovascular disease frequently result in complication and have well-documented guidelines for management, the management of chronic hemolytic and vascular-related complications, such as priapism, leg ulcers, and pulmonary hypertension, is not as well recognized despite their increasing reported prevalence and association with morbidity and mortality. This chapter therefore reviews the current updates on diagnosis and management of priapism, leg ulcers, and pulmonary hypertension.<\/jats:p>","DOI":"10.1182\/hematology.2021000275","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:14:15Z","timestamp":1639138455000},"page":"411-417","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease"],"prefix":"10.1182","volume":"2021","author":[{"given":"Roberta C.G.","family":"Azbell","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Department of Internal Medicine, Columbus, OH"},{"name":"Division of Hospital Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal Chandarana","family":"Desai","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Department of Internal Medicine, Columbus, OH"},{"name":"Division of Hematology and Oncology, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"9757","key":"2021121012073906700_hem2021000275C1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"2021121012073906700_hem2021000275C2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/17474086.2020.1758555","article-title":"Sickle cell disease as a vascular disorder","volume":"13","author":"Ofori-Acquah","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2021121012073906700_hem2021000275C3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajh.24134","article-title":"How we treat sickle cell patients with leg ulcers clinical cases 40th anniversary issue","volume":"91","author":"Minniti","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"2021121012073906700_hem2021000275C4","first-page":"CD008394","article-title":"Interventions for treating leg ulcers in people with sickle cell disease","volume":"2014","author":"Mart\u00ed-Carvajal","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2021121012073906700_hem2021000275C5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/archinte.1980.00330220022011","article-title":"Priapism and impotence in homozygous sickle cell disease","volume":"140","author":"Emond","year":"1980","journal-title":"Arch Intern Med"},{"issue":"6","key":"2021121012073906700_hem2021000275C6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11934-006-0061-6","article-title":"Priapism: new concepts in the pathophysiology and new treatment strategies","volume":"7","author":"Bivalacqua","year":"2006","journal-title":"Curr Urol Rep"},{"issue":"4","key":"2021121012073906700_hem2021000275C7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism","volume":"170","author":"Montague","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"2021121012073906700_hem2021000275C8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood.V95.1.78","article-title":"Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism","volume":"95","author":"Mantadakis","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2021121012073906700_hem2021000275C9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1743-6109.2011.02317.x","article-title":"Priapism and sickle\u2013cell anemia: diagnosis and nonsurgical therapy","volume":"9","author":"Broderick","year":"2012","journal-title":"J Sex Med"},{"issue":"1","key":"2021121012073906700_hem2021000275C10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jca.21394","article-title":"Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease","volume":"31","author":"Ballas","year":"2016","journal-title":"J Clin Apher"},{"issue":"5","key":"2021121012073906700_hem2021000275C11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0022-5347(17)35817-2","article-title":"Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome","volume":"150","author":"Siegel","year":"1993","journal-title":"J Urol"},{"issue":"6","key":"2021121012073906700_hem2021000275C12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-3476(05)81954-7","article-title":"Neurologic events after partial exchange transfusion for priapism in sickle cell disease","volume":"120","author":"Rackoff","year":"1992","journal-title":"J Pediatr"},{"issue":"9","key":"2021121012073906700_hem2021000275C13","first-page":"CD004198","article-title":"Treatments for priapism in boys and men with sickle cell disease","volume":"9","author":"Chinegwundoh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2021121012073906700_hem2021000275C14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jsxm.2020.11.010","article-title":"Rare disorders of painful erection: a cohort study of the investigation and management of stuttering priapism and sleep-related painful erection","volume":"18","author":"Johnson","year":"2021","journal-title":"J Sex Med"},{"issue":"4","key":"2021121012073906700_hem2021000275C15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2010-09-306167","article-title":"Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity","volume":"118","author":"Machado","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2021121012073906700_hem2021000275C16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11255-014-0737-7","article-title":"Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature","volume":"46","author":"Anele","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"2021121012073906700_hem2021000275C17","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/00005392-199805000-00065","article-title":"Hydroxyurea in the treatment of sickle cell associated priapism","volume":"159","author":"Hassan","year":"1998","journal-title":"J Urol"},{"issue":"8","key":"2021121012073906700_hem2021000275C18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00129334-200410000-00010","article-title":"Leg ulcers in sickle cell disease","volume":"17","author":"Trent","year":"2004","journal-title":"Adv Skin Wound Care"},{"issue":"9","key":"2021121012073906700_hem2021000275C19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.ASW.0000419408.37323.0c","article-title":"Sickle cell disease and leg ulcers","volume":"25","author":"Ladizinski","year":"2012","journal-title":"Adv Skin Wound Care"},{"issue":"8","key":"2021121012073906700_hem2021000275C20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ajh.22065","article-title":"Laboratory and echocardiography markers in sickle cell patients with leg ulcers","volume":"86","author":"Minniti","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"2021121012073906700_hem2021000275C21","first-page":"164","article-title":"Isoxsuprine hydrochloride in the therapy of sickle cell leg ulceration","volume":"26","author":"Serjeant","year":"1977","journal-title":"West Indian Med J"},{"issue":"5","key":"2021121012073906700_hem2021000275C22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2010.08395.x","article-title":"A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers","volume":"151","author":"McMahon","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2021121012073906700_hem2021000275C23","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2352-3026(14)00019-2","article-title":"Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial","volume":"1","author":"Minniti","year":"2014","journal-title":"Lancet Haematol"},{"issue":"1","key":"2021121012073906700_hem2021000275C24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/asheducation-2014.1.425","article-title":"Pulmonary hypertension in sickle cell disease: diagnosis and management","volume":"2014","author":"Ataga","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"2021121012073906700_hem2021000275C25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease","volume":"127","author":"Gordeuk","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2021121012073906700_hem2021000275C26","first-page":"310","article-title":"Risk of death in sickle cell disease","volume":"296","author":"Machado","year":"2006","journal-title":"Vasc Med"},{"issue":"4","key":"2021121012073906700_hem2021000275C27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2011.08777.x","article-title":"NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease","volume":"154","author":"Machado","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2021121012073906700_hem2021000275C28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A hemodynamic study of pulmonary hypertension in sickle cell disease","volume":"365","author":"Parent","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"2021121012073906700_hem2021000275C29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"2021121012073906700_hem2021000275C30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2006.06110.x","article-title":"Pulmonary hypertension in patients with sickle cell disease: a longitudinal study","volume":"134","author":"Ataga","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"2021121012073906700_hem2021000275C31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201401-0065ST","article-title":"An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease","volume":"189","author":"Klings","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2021121012073906700_hem2021000275C32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.12453","article-title":"Longitudinal study of echocardiography-derived tricuspid regurgitant jet velocity in sickle cell disease","volume":"162","author":"Desai","year":"2013","journal-title":"Br J Haematol"},{"issue":"23","key":"2021121012073906700_hem2021000275C33","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"key":"2021121012073906700_hem2021000275C34","unstructured":"National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel, 2014. Accessed 26May2019. https:\/\/www.nhlbi.nih.gov\/sites\/default\/files\/media\/docs\/sickle-cell-disease-report 020816_0.pdf"},{"issue":"8","key":"2021121012073906700_hem2021000275C35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/heartjnl-2019-314810","article-title":"Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure","volume":"106","author":"Wood","year":"2020","journal-title":"Heart"},{"issue":"4","key":"2021121012073906700_hem2021000275C36","doi-asserted-by":"crossref","first-page":"L314","DOI":"10.1152\/ajplung.00252.2014","article-title":"Vasculopathy and pulmonary hypertension in sickle cell disease","volume":"308","author":"Potoka","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"2021121012073906700_hem2021000275C37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2021121012073906700_hem2021000275C38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2141.2009.07906.x","article-title":"Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease","volume":"147","author":"Minniti","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2021121012073906700_hem2021000275C39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.2005.05625.x","article-title":"Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension","volume":"130","author":"Machado","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2021121012073906700_hem2021000275C40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2141.2005.05432.x","article-title":"Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension","volume":"129","author":"Machado","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2021121012073906700_hem2021000275C41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1164\/rccm.200208-967OC","article-title":"Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?","volume":"168","author":"Morris","year":"2003","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/411\/1851512\/411azbell.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/411\/1851512\/411azbell.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:14:54Z","timestamp":1639138494000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/411\/482956\/Treatment-dilemmas-strategies-for-priapism-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000275","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}